Provectus Biopharmaceuticals Inc (PVCT)

[pacificnorthwest1]

Reports from 50th American Society of Clinical Oncology (ASCO) Annual Meeting


Friday July 18, 2014
Immunotherapy takes centre stage in melanoma

An article appearing in the July/August 2014 issue of Oncology News reports that data presented at ASCO underline the way immunotherapy is reshaping the treatment of melanoma, not just in metastatic melanoma (the combination of nivolumab and ipilimumab, and pembrolizumab), but also in locally advanced cutaneous melanoma with PV-10.

A reprint of the Oncology News article is available at www.pvct.com/news/OncologyNews-Jul-2014.pdf
[url]
www.pvct.com/news/OncologyNews-Jul-2014.pdf[/url][tag]insert-text-here[/tag]

on the Provectus website.



123tom
Yes Kudos to you...so far your thoughts on the possible lows, seem to be in view as a possibility again.
I will admit, I have changed the bid I placed in that July 4th week, of .70, to the 60's now.........

THE QUESTIONS of the MONTH -----or YEAR:
1. Will the gap of .63 and or .64 really happen??????

2. If a person has a bid at .65 is it more sure to happen than a .63/.64 bid, or will all the buyers the exchange can find be needed since there will not be too many buyers at this point, and in that case we may be even lower like .60 or .50's?????